Drug safety: The roles of big data and clinical experience
Indian Journal of Medical Ethics · 2025
DOI: 10.20529/ijme.2025.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Medical Ethics, 2025. Verfasst von David Healy. Beteiligte Einrichtung: Chief Scientific Officer, Data Based Medicine, UNITED KINGDOM. Hauptthemen laut MEDLINE: Big Data, Pharmacovigilance, Artificial Intelligence, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Following the pharmacovigilance crises of 2004 involving the use of Vioxx and antidepressants in minors, medicine regulators turned to big data, also called real-world evidence, to support their efforts to establish the safety of treatment protocols. In many areas of drug development, big data can clearly play a part; but to date, it has not helped resolve safety issues. Developments in artificial intelligence may help clarify the respective roles of big data and clinical expertise in pharmacovigilance in surprising ways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chief Scientific Officer, Data Based Medicine, UNITED KINGDOM.
Zitieren
APA
Healy, D. (2025). Drug safety: The roles of big data and clinical experience. Indian Journal of Medical Ethics. https://doi.org/10.20529/ijme.2025.017
Vancouver
Healy D. Drug safety: The roles of big data and clinical experience. Indian Journal of Medical Ethics. 2025. doi:10.20529/ijme.2025.017
BibTeX
@article{Healy2025,
author = {Healy, David},
title = {Drug safety: The roles of big data and clinical experience},
journal = {Indian Journal of Medical Ethics},
year = {2025},
doi = {10.20529/ijme.2025.017}
}
EUVIMED